Cheapest Wegovy or Saxenda UK - Compare & Save

Our Pricing

Wegovy or Saxenda: Which Weight Loss Injection Is Right for You?

Choosing between Wegovy or Saxenda can feel overwhelming when both are proven GLP-1 weight loss injections licensed in the UK. As a UK-registered pharmacy with thousands of patients successfully treated, we've guided countless individuals through this exact decision. This comprehensive comparison examines clinical efficacy, cost differences, side effect profiles, and practical switching considerations to help you make an informed choice with your prescriber.

Wegovy or Saxenda: Understanding the Key Differences

When deciding between Wegovy or Saxenda, the fundamental difference lies in their active ingredients and dosing frequency. Wegovy contains semaglutide, a once-weekly GLP-1 receptor agonist, while Saxenda contains liraglutide, requiring daily injections [1]. Both medications work by mimicking the GLP-1 hormone to reduce appetite, slow gastric emptying, and improve blood sugar regulation, but their pharmacological profiles differ significantly.

Semaglutide in Wegovy has a longer half-life of approximately 7 days compared to liraglutide's 13 hours, explaining the weekly versus daily injection schedule [2]. This pharmacokinetic difference affects not only convenience but also how each medication maintains therapeutic levels in your system. Clinical trials demonstrate that both treatments require gradual dose escalation to minimise gastrointestinal side effects, though the titration schedules differ substantially between Wegovy or Saxenda protocols.

From a practical standpoint, Wegovy offers the convenience of 52 injections per year versus Saxenda's 365, which many patients find significantly impacts treatment adherence. However, Saxenda's daily dosing allows for more immediate dose adjustments if side effects occur, providing flexibility that some prescribers prefer during the initial treatment phase.

Clinical Efficacy: Wegovy or Saxenda for Weight Loss Results

The STEP clinical trial programme for Wegovy demonstrated average weight loss of 15-17% of initial body weight over 68 weeks in participants without diabetes [1]. By comparison, the SCALE trials for Saxenda showed average weight loss of 8-9% over 56 weeks [3]. When patients ask whether Wegovy or Saxenda delivers superior results, these head-to-head data suggest semaglutide produces approximately double the weight reduction of liraglutide.

However, individual response varies considerably, and some patients achieve excellent results with Saxenda while others may not tolerate Wegovy's side effect profile. In our clinical experience at Cured Pharmacy, we've observed that patients who respond well to one GLP-1 agonist often show good tolerability to others, though this isn't universal. The choice between Wegovy or Saxenda should factor in your personal medical history, previous medication responses, and lifestyle considerations alongside average trial data.

It's worth noting that both medications are licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity such as hypertension or type 2 diabetes. NICE guidance recognises both Wegovy and Saxenda as effective pharmacological interventions when used alongside reduced-calorie diet and increased physical activity [4].

Real-World Outcomes Beyond Clinical Trials

While controlled trials provide valuable efficacy data for Wegovy or Saxenda, real-world evidence from UK prescribing patterns shows treatment persistence rates differ between the two medications. Registry studies indicate that weekly Wegovy injections correlate with higher 12-month continuation rates compared to daily Saxenda, likely reflecting the convenience factor [2]. However, patients who establish a consistent daily routine often maintain excellent adherence to Saxenda throughout their treatment journey.

Cost Comparison: Wegovy or Saxenda Pricing at Cured Pharmacy

Price is a decisive factor when choosing between Wegovy or Saxenda, and Cured Pharmacy offers both at the most competitive UK pricing. Saxenda is available from £69.00 per pen, while Wegovy starts from £69.00 per pen. Over a typical treatment month, Saxenda requires approximately 5 pens (daily injections) compared to Wegovy's 4 pens (weekly injections), making the monthly cost calculation essential to your decision.

When you calculate total monthly expenditure, Wegovy or Saxenda costs work out relatively comparable at Cured Pharmacy's pricing, though Saxenda often represents slightly lower monthly outlay during maintenance dosing. We offer transparent upfront pricing before your clinical consultation, and new patients can access £20 off their first order using code Weightlossnew, reducing initial treatment costs further.

Unlike many UK pharmacies, we guarantee the lowest prices and provide genuine UK-licensed medications dispensed by our GPhC-registered team. Superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every prescription meets strict regulatory standards, so you're never choosing between affordability and quality when selecting Wegovy or Saxenda from Cured Pharmacy.

Side Effects: Wegovy or Saxenda Tolerability Profile

Both Wegovy or Saxenda share a similar side effect profile typical of GLP-1 receptor agonists, with gastrointestinal symptoms being most common. Nausea, diarrhoea, constipation, and abdominal discomfort occur in 20-50% of users during dose escalation [1][3]. These effects typically diminish as your body adjusts, though some patients find one medication more tolerable than the other based on individual physiology.

In clinical trials, discontinuation rates due to adverse events were similar between Wegovy and Saxenda, ranging from 4-7% [2][3]. However, the weekly dosing of Wegovy means side effects, if they occur, persist longer between doses, whereas Saxenda's daily administration allows the medication to clear more quickly if you need to pause treatment. This pharmacological difference can influence prescriber recommendations when choosing Wegovy or Saxenda for patients with sensitive gastrointestinal systems.

Rare but serious side effects include pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (contraindicated in patients with personal or family history of medullary thyroid carcinoma). Both medications carry these warnings, and your prescriber will assess your complete medical history during consultation to determine whether Wegovy or Saxenda is appropriate for you.

Managing Side Effects During Treatment

Regardless of whether you choose Wegovy or Saxenda, following the prescribed dose escalation schedule significantly reduces side effect severity. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated helps minimise nausea and gastrointestinal discomfort. Our clinical team at Cured Pharmacy provides ongoing support throughout your treatment, and dose adjustments can be made subject to prescriber approval if side effects become problematic.

Switching Between Wegovy or Saxenda: Clinical Considerations

Many patients successfully switch between Wegovy or Saxenda based on tolerability, efficacy, or supply availability. Because both medications are GLP-1 receptor agonists, cross-titration is generally straightforward, though it must be supervised by a UK prescriber. If you're currently on Saxenda and considering Wegovy, your prescriber will typically start you at Wegovy's lowest dose (0.25mg weekly) even if you're on maximum-dose Saxenda, allowing your system to adjust to the different pharmacokinetics [5].

Conversely, switching from Wegovy to Saxenda requires transitioning from weekly to daily injections, usually beginning Saxenda at 0.6mg daily and escalating according to the standard titration schedule. The washout period between medications is minimal due to their similar mechanisms, though some prescribers prefer a 1-2 week overlap during transition to maintain appetite suppression continuity when moving between Wegovy or Saxenda.

At Cured Pharmacy, we've supported hundreds of patients through medication switches, and our prescribers consider your treatment history, current dose, response to date, and reasons for switching when creating your personalised transition plan. Whether you're switching due to side effects, cost considerations, or supply issues, clinical guidance ensures the change is safe and effective.

Making Your Decision: Wegovy or Saxenda at Cured Pharmacy

Choosing between Wegovy or Saxenda ultimately depends on your individual circumstances, preferences, and clinical profile. Wegovy offers superior weight loss results in trials and weekly convenience, making it ideal for patients who prioritise maximum efficacy and minimal injection frequency. Saxenda provides a lower starting price point, daily dosing flexibility, and the option for more granular dose adjustments, which some patients and prescribers prefer.

Both medications require commitment to lifestyle changes including reduced-calorie nutrition and increased physical activity to achieve optimal results [4]. Neither Wegovy or Saxenda is a standalone solution, and clinical trials consistently show best outcomes when pharmacotherapy supports comprehensive behaviour modification. Our UK-registered clinical team completes a thorough assessment during your online consultation to determine which treatment aligns with your medical history and weight loss goals.

Starting your treatment journey at Cured Pharmacy means accessing both Wegovy and Saxenda at the UK's most competitive pricing, with transparent costs shown before consultation, discreet packaging, and ongoing clinical support. Your prescription is assessed and approved by UK-registered prescribers, dispensed by our GPhC-registered pharmacy team, and delivered with next-day options available. Use code Weightlossnew for £20 off your first order and begin your medically-supervised weight loss programme today.

How to Start Treatment at Cured Pharmacy

Beginning treatment with Wegovy or Saxenda requires just three simple steps: complete our free online clinical assessment (under 3 minutes), receive prescriber review and approval, then have your medication dispensed and dispatched with discreet next-day delivery available. Our superintendent pharmacist Tarun Kumar and the clinical team ensure every prescription meets MHRA and GPhC standards, so you can trust you're receiving genuine UK-licensed medication at the lowest guaranteed price.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22. [accessed 15 August 2026]
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). [accessed 15 August 2026]
5. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4mg solution for injection in pre-filled pen: Summary of Product Characteristics. [accessed 15 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.